Aegle Therapeutics isolates extracellular vesicles (EVs) secreted by allogeneic bone marrow derived mesenchymal stem cells (BM-MSCs) to treat severe dermatological conditions including burns and epidermaolysis bullosa (EB), a rare pediatric connective tissue disorder. Its proprietary extracellular vesicle isolation technology allows them to harness the healing power of mesenchymal stem cells without the risk of cell proliferation or engraftment, with higher production yields and at a lower cost.
Status: Active
Announcement Date: January 2020
